Poorly known aspects of flattening the curve of COVID-19

Alain Debecker; Theodore Modis

doi:10.1101/2020.06.09.20126128

Abstract

This work concerns the too-often mentioned flattening of the curve of COVID-19. The diffusion of the virus is analyzed with logistic-curve fits on the 25 countries most affected at the time of the writing and in which the diffusion curve was more than 95% completed. A negative correlation observed between the final number of infections and the slope of the logistic curve corroborates a result obtained long time ago via an extensive simulation study. There is both theoretical arguments and experimental evidence for the existence of such correlations. The flattening of the curve results in a retardation of the curve’s midpoint, which entails an increase in the final number of infections. It is possible that more lives are lost at the end by this process. Our analysis also permits evaluation of the various governments’ interventions in terms of rapidity of response, efficiency of the actions taken (the amount of flattening achieved), and the number of days by which the curve was delayed. Not surprisingly, early decisive response proves to be the optimum strategy among the countries studied.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

This is not a clinical study

Funding Statement

No external funding was received

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

There was no need for IRB/oversight approval

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes